{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:28:08Z","timestamp":1770481688600,"version":"3.49.0"},"reference-count":16,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T00:00:00Z","timestamp":1370390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Telaprevir\u2010based triple therapy is highly effective for chronic hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>. However, concern has been expressed over the high frequency and severity of its dermatological side\u2010effects compared with those associated with peginterferon (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>) and ribavirin (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) therapy. Thus, here, we evaluated the dermatological adverse reactions of telaprevir\u2010based triple therapy in <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apanese multicenter phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> clinical trials in an attempt to characterize the dermatological side\u2010effects and establish appropriate management plans. In these trials, 126 treatment\u2010na\u00efve patients and 141 treatment\u2010failure patients were administrated telaprevir, <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010\u03b1\u20102b and <jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> for 12\u00a0weeks followed by <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010\u03b1\u20102b and <jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> for another 12\u00a0weeks (T12\/<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>24 group), and 63 treatment\u2010na\u00efve patients were administrated <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010\u03b1\u20102b and <jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> for 48\u00a0weeks (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>48 group). Dermatological adverse reactions developed in over 80% patients in both groups, and most of them were grade 1 or 2. In the <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>12\/<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>24 group, there were more grade 2 or grade 3 events, and the time to onset was earlier than that in the <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>48 group. Most reactions could be managed with topical corticosteroids and oral antihistamines, and the rates of discontinuation due to dermatological reactions were not high even in the <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>12\/<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>24 group. In the <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>12\/<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>24 group, however, two cases of <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>tevens\u2013<jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>ohnson syndrome and one case of drug rash with eosinophilia and systemic symptoms, which corresponds to drug\u2010induced hypersensitivity syndrome in <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apan, were reported. For appropriate treatments of individual dermatological adverse reactions, the judgment of discontinuation of antiviral drugs and treatment based on the severity are extremely important in this triple therapy.<\/jats:p>","DOI":"10.1111\/1346-8138.12199","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T09:55:18Z","timestamp":1370426118000},"page":"587-595","source":"Crossref","is-referenced-by-count":15,"title":["Dermatological side\u2010effects of telaprevir\u2010based triple therapy for chronic hepatitis <scp>C<\/scp> in phase <scp>III<\/scp> trials in <scp>J<\/scp>apan"],"prefix":"10.1111","volume":"40","author":[{"given":"Hideshi","family":"Torii","sequence":"first","affiliation":[{"name":"Division of Dermatology Social Insurance Central General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Sueki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Aoki","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichimaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamitaro","family":"OHtsuki","sequence":"additional","affiliation":[{"name":"Departments of Dermatology Jichi Medical University Tochigi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,6,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.899-909.2006"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806104"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807650"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.07.016"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01528.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01514.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01640.x"},{"key":"e_1_2_6_11_1","first-page":"29","article-title":"Dermatological side effects","volume":"9","author":"Lubbe J","year":"2008","journal-title":"Hot Topics in Viral Hepatitis"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06931.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1155\/2009\/651952","article-title":"A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin","volume":"23","author":"Mistry N","year":"2009","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_6_14_1","first-page":"1555","article-title":"Local cutaneous side effects of interferons","volume":"30","author":"Charron A","year":"2001","journal-title":"Presse Med"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.938"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.08.006"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.12199","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.12199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:27:34Z","timestamp":1696519654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.12199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,5]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/1346-8138.12199"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.12199","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,5]]}}}